Who are DTaP-IPV combination vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): H-VA dual therapy, Infanrix® Penta, Pentacel (DPTaP+Hib), Infanrix TM, TDaP-IPV vaccine, sIPV+DTaP+MMR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dtap-ipv-combination-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

DTaP-IPV combination vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DTaP-IPV combination vaccine (DTaP-IPV combination vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination vaccine. Area: Immunology.

phase 3 Combination vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

DTaP-IPV combination vaccine (DTaP-IPV combination vaccine) — Boryung Biopharma Co., Ltd.. This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by delivering inactivated toxins and viral antigens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
DTaP-IPV combination vaccine TARGET	DTaP-IPV combination vaccine	Boryung Biopharma Co., Ltd.	phase 3	Combination vaccine
H-VA dual therapy	H-VA dual therapy	The First Affiliated Hospital of Nanchang University	marketed	Combination vaccine
Infanrix® Penta	Infanrix® Penta	GlaxoSmithKline	marketed	Combination vaccine
Pentacel (DPTaP+Hib)	Pentacel (DPTaP+Hib)	The Hospital for Sick Children	marketed	Combination vaccine
Infanrix TM	Infanrix TM	GlaxoSmithKline	marketed	Inactivated combination vaccine
TDaP-IPV vaccine	TDaP-IPV vaccine	Radboud University Medical Center	marketed	combination vaccine
sIPV+DTaP+MMR	sIPV+DTaP+MMR	China National Biotec Group Company Limited	marketed	Combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination vaccine class)

GlaxoSmithKline · 22 drugs in this class
Sanofi Pasteur, a Sanofi Company · 8 drugs in this class
Serum Institute of India Pvt. Ltd. · 3 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
Sanofi · 3 drugs in this class
PT Bio Farma · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
The Hospital for Sick Children · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DTaP-IPV combination vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtap-ipv-combination-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab